Eliot has held senior research, and research leadership positions in drug discovery and development in the pharmaceutical industry for more than 35 years. Previously, he led R&D teams at GlaxoSmithKline for 25 years, most recently as a Senior Vice President Drug Discovery and Development, where he was involved in cardiovascular, metabolic, renal and oncology therapeutics, with both small, large and peptide molecules. Under Eliot’s leadership GSK discovered and advanced into clinical development and to market, Coreg® (carvedilol) for heart failure, the HER2 receptor inhibitor Tykerb® (lapatinib) for metastatic breast cancer, and the tyrosine kinase angiogenesis inhibitor Votrient® (pazopanib) for advanced renal cell carcinoma. Eliot has been a founder of biotech companies Venuvics Pharmaceuticals, AltheRx Pharmaceuticals, and Velicept Pharmaceuticals. He joined Bessor Pharm as a consultant in 2016. Eliot is an author on more than 275 publications on drug discovery and development for new therapeutic targets and active in the field of Pharmacology as an Adjunct Professor of Pharmacology at Drexel and is a member of for several Biotech SABs. He is Editor for NC-IUPHAR, is on the Editorial Board for Pharmacological Reviews and British Journal of Pharmacology and is also Specialty Editor-in-Chief for Frontiers in Pharmacology—Cardiovascular Pharmacology & Urogenital Disorders.

Eliot holds a BS in Pharmacy from the Massachusetts College of Pharmacy and a PhD in Pharmacology from the Tulane University School of Medicine. His graduate research on the discovery of nitric oxide as an important biological mediator contributed to the Nobel Prize in 1998. He was honored with the Prix Galien Award and Special Commendation for Innovation Research for endothelin receptors. In 2008, Dr. Ohlstein received PhRMA's highest honor, the Discoverer's Award, for his work on GSK's Coreg® (carvedilol), the "standard of care" for chronic heart failure.